This study is being conducted in participants with geographic atrophy (GA) secondary to
age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of
ANX007 reduce GA lesion growth rate. The results will be used to guide further development of
ANX007 in participants with geographic atrophy. The total duration of participation is
expected to be approximately 19 months.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.